You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR VASOPRESSIN IN SODIUM CHLORIDE 0.9%


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Vasopressin In Sodium Chloride 0.9%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed Northwestern University 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status Northwestern University 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vasopressin In Sodium Chloride 0.9%

Condition Name

Condition Name for Vasopressin In Sodium Chloride 0.9%
Intervention Trials
Septic Shock 24
Hyponatremia 13
Healthy 11
Congestive Heart Failure 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vasopressin In Sodium Chloride 0.9%
Intervention Trials
Shock 36
Shock, Septic 28
Heart Failure 22
Hemorrhage 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vasopressin In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Vasopressin In Sodium Chloride 0.9%
Location Trials
United States 320
Canada 28
Germany 22
Italy 17
Greece 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vasopressin In Sodium Chloride 0.9%
Location Trials
California 21
New York 19
Texas 17
Ohio 16
Illinois 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vasopressin In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Vasopressin In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Phase 4 50
Phase 3 34
Phase 2/Phase 3 17
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vasopressin In Sodium Chloride 0.9%
Clinical Trial Phase Trials
Completed 135
Recruiting 37
Unknown status 27
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vasopressin In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Vasopressin In Sodium Chloride 0.9%
Sponsor Trials
Vantia Ltd 8
Multidisciplinary Association for Psychedelic Studies 7
Otsuka Pharmaceutical Co., Ltd. 7
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vasopressin In Sodium Chloride 0.9%
Sponsor Trials
Other 311
Industry 71
NIH 16
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Vasopressin in Sodium Chloride 0.9%: Clinical Trials, Market Analysis, and Projections

Introduction

Vasopressin, also known as antidiuretic hormone (ADH), is a crucial medication in critical care settings, particularly for managing vasodilatory shock. When combined with 0.9% sodium chloride, it forms a solution that is widely used to increase blood pressure in patients who are unresponsive to other treatments. Here, we delve into the clinical trials, market analysis, and future projections for Vasopressin in Sodium Chloride 0.9%.

Clinical Trials and Stability Studies

Stability of Vasopressin Solutions

Recent studies have focused on the stability of vasopressin solutions when diluted and stored in polyvinyl chloride (PVC) containers. A study published in the American Journal of Health-System Pharmacy evaluated the physical and chemical stability of vasopressin diluted to 0.2 units/mL with 0.9% sodium chloride injection. The results showed that these solutions remained physically stable and exhibited less than 10% degradation over 10 days of refrigerated storage, allowing for a beyond-use date (BUD) of 10 days[1][5].

Clinical Use and Efficacy

Vasopressin is clinically used to increase systemic vascular resistance and arterial pressure, particularly in patients with vasodilatory shock who are unresponsive to catecholamines and fluids. Clinical studies have demonstrated its efficacy in improving survival chances and reducing the need for catecholamine vasopressors in patients at risk of vasoplegic syndrome after cardiac surgery[3].

Market Analysis

Market Size and Growth

The global vasopressin for vasoplegic shock market has seen significant growth and is projected to continue this trend. In 2019, the market size was USD 890.9 million, and it is expected to reach USD 2,657.9 million by 2027, exhibiting a Compound Annual Growth Rate (CAGR) of 14.8% during the forecast period. This growth is driven by the increasing prevalence of sepsis, the rising number of cardiac surgeries, and the impact of the COVID-19 pandemic on cardiac health[3].

Key Market Segments

The market is segmented into several key areas:

  • Sepsis: This segment holds a major share of the market due to the increasing prevalence and diagnosis of sepsis globally. For instance, the National Institute for Health and Care Excellence (NICE) estimates around 123,000 cases of sepsis in England annually, resulting in significant demand for vasopressin[3].
  • Post-Cardiac Surgery: The growing number of cardiac surgeries worldwide is another significant factor driving the demand for vasopressin. New treatment models and extensive research in this area are contributing to market growth[3].
  • Regional Markets: North America and Europe are key regions, with North America's market size standing at USD 561.3 million in 2019. The European market is also expected to see significant growth due to strong government investments in R&D and the launch of novel therapeutics[3].

Product Developments and Launches

Premix Vasopressin Solutions

Long Grove Pharmaceuticals has recently announced the launch of Premix Vasopressin solutions, which are designed to meet the critical care needs of hospital pharmacies. These premix solutions are available in concentrations of 20 units/100 mL (0.2 units/mL) and 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride. This development addresses the need for premix vasopressin with a long shelf life, providing immediate value to hospital pharmacies and their patients[2].

Regulatory and Safety Considerations

Dosage and Administration

Vasopressin in Sodium Chloride Injection is administered via intravenous infusion, typically at doses ranging from 0.01 to 0.07 units/minute. The solution is supplied in 100-mL single-dose containers with concentrations of 20 units (0.2 units/mL) or 40 units (0.4 units/mL) in 0.9% sodium chloride[4].

Contraindications and Warnings

The medication is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin. It can worsen cardiac function and may cause reversible diabetes insipidus. High doses of vasopressin can lead to severe side effects, including vasoconstriction of various vascular beds and hyponatremia[4].

Impact of COVID-19

The COVID-19 pandemic has had a positive impact on the vasopressin market due to the increased risk of cardiac syndromes in COVID-19 patients. This has led to a surge in demand for vasopressin drugs, as they are critical in managing vasodilatory shock in these patients[3].

Future Projections

Market Growth Drivers

  • Increasing Prevalence of Sepsis: The growing incidence of sepsis worldwide is expected to continue driving the demand for vasopressin.
  • Rising Number of Cardiac Surgeries: The increasing number of cardiac surgeries globally will further boost the market.
  • Advancements in Treatment Models: Ongoing research and the introduction of new treatment models for vasoplegic shock will contribute to market growth[3].

Challenges and Limitations

  • Side Effects: Higher doses of vasopressin can lead to significant side effects, which might act as a restraining factor for the market.
  • Regulatory Approvals: The need for regulatory approvals and the complexity of manufacturing processes can pose challenges to market expansion[3].

Key Takeaways

  • Stability and Shelf Life: Vasopressin solutions diluted to 0.2 units/mL in 0.9% sodium chloride can be stored for up to 10 days under refrigeration with less than 10% degradation.
  • Market Growth: The global vasopressin market is projected to grow significantly, driven by the increasing prevalence of sepsis and the rising number of cardiac surgeries.
  • Product Developments: Premix vasopressin solutions are being introduced to meet critical care needs, offering a long shelf life and convenience.
  • Regulatory Considerations: The medication has specific contraindications and warnings, including potential worsening of cardiac function and reversible diabetes insipidus.

FAQs

What is the primary use of Vasopressin in Sodium Chloride 0.9%?

Vasopressin in Sodium Chloride 0.9% is primarily used to increase blood pressure in patients with vasodilatory shock who are unresponsive to other treatments.

What are the common concentrations of Premix Vasopressin solutions?

Premix Vasopressin solutions are available in concentrations of 20 units/100 mL (0.2 units/mL) and 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride[2].

How stable are vasopressin solutions when stored in PVC containers?

Vasopressin solutions diluted to 0.2 units/mL in 0.9% sodium chloride remain physically stable and show less than 10% degradation over 10 days of refrigerated storage in PVC containers[1][5].

What are the potential side effects of high doses of vasopressin?

High doses of vasopressin can lead to severe side effects, including vasoconstriction of various vascular beds, hyponatremia, and worsening cardiac function[4].

How has the COVID-19 pandemic impacted the vasopressin market?

The COVID-19 pandemic has increased the demand for vasopressin due to the higher risk of cardiac syndromes in COVID-19 patients, thereby positively impacting the market[3].

Sources

  1. Extended stability of vasopressin 0.2 unit/mL in PVC containers. PubMed, 2023.
  2. Long Grove will soon offer Premix Vasopressin to help relieve stress on critical care. PR Newswire, 2024.
  3. Vasopressin for Vasoplegic Shock Market Size & Growth [2027]. Fortune Business Insights.
  4. VASOPRESSIN IN SODIUM CHLORIDE INJECTION. FDA, 2024.
  5. Extended stability of vasopressin 0.2 unit/mL in PVC containers. American Journal of Health-System Pharmacy, 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.